Novartis, Foundation Medicine announce new agreement to offer genomic analysis

Foundation Medicine today announced a new agreement with Novartis to provide comprehensive genomic analysis in support of Novartis' clinical oncology programs.    

Novartis plans to use Foundation Medicine's molecular information platform across many of Novartis' Phase 1 and 2 oncology clinical programs. The pilot program established between Novartis and Foundation Medicine 18 months ago has generated very interesting data, and this type of tumor genomic profiling has become an essential component of Novartis' clinical trials. The partnership consists of running Foundation Medicine's comprehensive genomic profiling on most Phase 1 and 2 clinical trial enrollees over the next three years. The partnership aims to accelerate the development of Novartis' broad portfolio of targeted cancer therapeutics and ultimately expand treatment options for patients.

"The comprehensive molecular assessment of Novartis' Oncology clinical trial samples is expected to help to bring potentially lifesaving therapies to the right patients more quickly, and we expect that the wealth of molecular information will help fundamentally improve the way cancer is understood and treated," said Michael J. Pellini, M.D., president and CEO, Foundation Medicine. "We are pleased to see our collaboration mature into a significant relationship between Foundation Medicine and Novartis."    

Source:

Foundation Medicine    

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
A traditional Chinese medicine could help treat COVID‐19 symptoms